US Melanoma Market Share

US Melanoma Market Overview

The US melanoma market is anticipated to reach USD 5.73 Billion by 2030 at 10.8% CAGR during the forecast period 2022-2030.

Melanoma is a type of cancer that develops from pigment containing cells known as melanocytes. It is the most dangerous type of skin cancer. Sometimes they develop from moles showing significant change in color, increase in size, itchiness, irregular edges, changein color or skin breakdown. Exposure to ultra violet light in people with low pigment levels. The tumor can be either malignant or benign. Types of melanoma are superficial spreading melanoma, nodular melanoma, lentigo maglina melanoma, acral lentigious melanoma and others. About 98% of melanoma is localized in the US. Skin cancer are most common cancers in the US. Treatment available for melanoma include biologic therapy, immune therapy, radiation therapy, chemotherapy and surgery. Ultra violet exposure is known as risk factor of melanoma. Superficial spreading melanoma is the type of melanoma affecting large number of people in the US. The disease is more common in men than women.

US Melanoma Market Segment Insights:

US melanoma market has been segmented on the basis of type (superficial spreading, nodular, lentigo maglina, acral lentigious and others), by gender (male and female), by treatment (immunotherapy, biologic therapy, radiation therapy, chemotherapy, surgery and others), by diagnosis (ABCDE, ugly duckling, biopsy, and others) and by end users (hospitals, pharmaceutical companies, research centers, clinics, laboratories).

Regional Analysis of Melanoma Market:

Melanoma market in the US is divided into states comprising of Georgia, New Jersey, North Carolina, New York, Florida, Illinois, Ohio, Pennsylvania, Texas, Washington, California and, Virginia and Rest of US. California accounts for the largest market for melanoma in US followed by Florida and Ohio. California and Florida are key regions for melanoma market. Large number of melanoma cases are found in this region.  New York is the third largest market after Florida. According to American Society of Dermatology, prevalence of melanoma is gradually increasing.  and this spreads across the body. Number of skin cancer patients is growing steadily in Florida and Texas. This is due to their exposure to ultraviolet rays and extensive use of tanning beds in these regions. Technological advancement in the field of treatment and diagnosis of melanoma in the US also drives this market. The Food and Drug Administration (FDA) classifies tanning beds as "moderate risk" devices.

Key Players for Melanoma Market:

Some of the Key Players in US melanoma market are: Amgen, Inc., Bristol-Myers Squibb, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Genentech Inc. Janssen Biotech, Inc., and Novartis International AG. Pfizer, Vical and Ziopharm.

The report for US melanoma market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current US melanoma market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the US melanoma market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Study Objectives of Melanoma Market:

• To provide detailed analysis of the market structure along with forecast for the next six years of various segments and sub-segments of the US melanoma market.


• To provide insights about factors affecting theUS melanoma market growth.


• To analyze the melanoma market based on various factors price analysis, supply chain analysis, Porters Five Force analysis etc.


• To provide historical and forecast revenue of the market segments and sub-segments with respect to the US.


• To provide country level analysis of the market with respect to the current US melanoma market size and future prospective.


• To provide country level analysis of the market for segments by type, by end users and its sub-segments.


• To provide overview of key players and their strategic profiling in the US melanoma market, comprehensively analyzing their core competencies, and drawing a competitive landscape for theUS melanoma market.


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the US melanoma market.

Intended Audience

• Hospitals


• Pharmaceutical companies


• Research and development (R&D) companies


• Academic medical institutes and universities


• Melanoma drug manufactures


• Melanoma drug suppliers